A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis.
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Jan 2017.
- 19 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History